168 related articles for article (PubMed ID: 36237272)
21. Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib.
Ou SI; Cui J; Schrock AB; Goldberg ME; Zhu VW; Albacker L; Stephens PJ; Miller VA; Ali SM
Lung Cancer; 2017 Jun; 108():228-231. PubMed ID: 28625641
[TBL] [Abstract][Full Text] [Related]
22. The clinical efficacy of combinatorial therapy of EGFR-TKI and crizotinib in overcoming MET amplification-mediated resistance from prior EGFR-TKI therapy.
Wang Y; Tian P; Xia L; Li L; Han R; Zhu M; Lizaso A; Qin T; Li M; Yu B; Mao X; Han-Zhang H; He Y
Lung Cancer; 2020 Aug; 146():165-173. PubMed ID: 32540560
[TBL] [Abstract][Full Text] [Related]
23. Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation.
Auliac JB; Pérol M; Planchard D; Monnet I; Wislez M; Doubre H; Guisier F; Pichon E; Greillier L; Mastroianni B; Decroisette C; Schott R; Le Moulec S; Arrondeau J; Cortot AB; Gerinière L; Renault A; Daniel C; Falchero L; Chouaid C
Lung Cancer; 2019 Jan; 127():96-102. PubMed ID: 30642559
[TBL] [Abstract][Full Text] [Related]
24. Molecular follow-up of first-line treatment by osimertinib in lung cancer: Importance of using appropriate tools for detecting EGFR resistance mutation C797S.
Fanjat Y; Barazzutti H; Di Mauro I; Tabary-Martin L; Duranton-Tanneur V; Gimet S; Bérard H; Pedeutour F
Cancer Genet; 2021 Aug; 256-257():158-161. PubMed ID: 34157597
[TBL] [Abstract][Full Text] [Related]
25. Acquired Concurrent EGFR T790M and Driver Gene Resistance From EGFR-TKIs Hampered Osimertinib Efficacy in Advanced Lung Adenocarcinoma: Case Reports.
Zeng Y; Feng Y; Fu G; Jiang J; Liu X; Pan Y; Hu C; Liu X; Wu F
Front Pharmacol; 2022; 13():838247. PubMed ID: 35462930
[TBL] [Abstract][Full Text] [Related]
26. EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples.
Rangachari D; To C; Shpilsky JE; VanderLaan PA; Kobayashi SS; Mushajiang M; Lau CJ; Paweletz CP; Oxnard GR; Jänne PA; Costa DB
J Thorac Oncol; 2019 Nov; 14(11):1995-2002. PubMed ID: 31377341
[TBL] [Abstract][Full Text] [Related]
27. Uncommon EGFR mutations associate with lower incidence of T790M mutation after EGFR-TKI treatment in patients with advanced NSCLC.
Yang S; Mao S; Li X; Zhao C; Liu Q; Yu X; Wang Y; Liu Y; Pan Y; Wang C; Gao G; Li W; Xiong A; Chen B; Sun H; He Y; Wu F; Chen X; Su C; Ren S; Zhou C
Lung Cancer; 2020 Jan; 139():133-139. PubMed ID: 31786475
[TBL] [Abstract][Full Text] [Related]
28. Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes.
Mu Y; Hao X; Xing P; Hu X; Wang Y; Li T; Zhang J; Xu Z; Li J
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2427-2433. PubMed ID: 32385709
[TBL] [Abstract][Full Text] [Related]
29. Complex EGFR mutations with secondary T790M mutation confer shorter osimertinib progression-free survival and overall survival in advanced non-small cell lung cancer.
Lin YT; Tsai TH; Wu SG; Liu YN; Yu CJ; Shih JY
Lung Cancer; 2020 Jul; 145():1-9. PubMed ID: 32387812
[TBL] [Abstract][Full Text] [Related]
30. ctDNA analysis reveals different molecular patterns upon disease progression in patients treated with osimertinib.
Romero A; Serna-Blasco R; Alfaro C; Sánchez-Herrero E; Barquín M; Turpin MC; Chico S; Sanz-Moreno S; Rodrigez-Festa A; Laza-Briviesca R; Cruz-Bermudez A; Calvo V; Royuela A; Provencio M
Transl Lung Cancer Res; 2020 Jun; 9(3):532-540. PubMed ID: 32676317
[TBL] [Abstract][Full Text] [Related]
31. Detection of an EML4-ALK fusion mutation secondary to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer: a case report.
Ren KH; Qin WW; Wang Y; Peng JC; Hu WX
Ann Palliat Med; 2022 Jul; 11(7):2503-2509. PubMed ID: 35927783
[TBL] [Abstract][Full Text] [Related]
32. Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation.
Hayakawa D; Takahashi F; Mitsuishi Y; Tajima K; Hidayat M; Winardi W; Ihara H; Kanamori K; Matsumoto N; Asao T; Ko R; Shukuya T; Takamochi K; Hayashi T; Suehara Y; Takeda Nakamura I; Ueno T; Kohsaka S; Mano H; Takahashi K
Thorac Cancer; 2020 Jan; 11(1):140-149. PubMed ID: 31758670
[TBL] [Abstract][Full Text] [Related]
33. A "triple whammy" in adenocarcinoma lung.
Patro M; Gothi D; Vaidya S; Sah RB
Lung India; 2019; 36(4):340-344. PubMed ID: 31290421
[TBL] [Abstract][Full Text] [Related]
34. Potential treatment strategy for the rare osimertinib resistant mutation EGFR L718Q.
Song Y; Jia Z; Wang Y; Wang Y; Liu P; Zhang S; Bing Z; Cao L; Cao Z; Rossi E; Zamarchi R; Denis MG; Camps C; Fernandez-Diaz AB; Liang N; Li S
J Thorac Dis; 2020 May; 12(5):2771-2780. PubMed ID: 32642185
[TBL] [Abstract][Full Text] [Related]
35. Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First- and Third-Generation EGFR TKIs and Shifts Allelic Configuration at Resistance.
Wang Z; Yang JJ; Huang J; Ye JY; Zhang XC; Tu HY; Han-Zhang H; Wu YL
J Thorac Oncol; 2017 Nov; 12(11):1723-1727. PubMed ID: 28662863
[TBL] [Abstract][Full Text] [Related]
36. Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: A multicentric retrospective French study.
Mehlman C; Cadranel J; Rousseau-Bussac G; Lacave R; Pujals A; Girard N; Callens C; Gounant V; Théou-Anton N; Friard S; Trédaniel J; Blons H; Dujon C; Duchemann B; Schischmanoff PO; Chinet T; Giroux Leprieur E
Lung Cancer; 2019 Nov; 137():149-156. PubMed ID: 31600593
[TBL] [Abstract][Full Text] [Related]
37. Combination Osimertinib and Gefitinib in C797S and T790M EGFR-Mutated Non-Small Cell Lung Cancer.
Arulananda S; Do H; Musafer A; Mitchell P; Dobrovic A; John T
J Thorac Oncol; 2017 Nov; 12(11):1728-1732. PubMed ID: 28843359
[TBL] [Abstract][Full Text] [Related]
38. Newly emergent acquired EGFR exon 18 G724S mutation after resistance of a T790M specific EGFR inhibitor osimertinib in non-small-cell lung cancer: a case report.
Zhang Y; He B; Zhou D; Li M; Hu C
Onco Targets Ther; 2019; 12():51-56. PubMed ID: 30588029
[TBL] [Abstract][Full Text] [Related]
39. HER2 Amplification in Advanced NSCLC Patients After Progression on EGFR-TKI and Clinical Response to EGFR-TKI Plus Pyrotinib Combination Therapy.
Gan J; Huang Y; Liao J; Pang L; Fang W
Onco Targets Ther; 2021; 14():5297-5307. PubMed ID: 34824536
[TBL] [Abstract][Full Text] [Related]
40. Acquired EGFR L718V Mutation as the Mechanism for Osimertinib Resistance in a T790M-Negative Non-Small-Cell Lung Cancer Patient.
Yang Z; Yang J; Chen Y; Shao YW; Wang X
Target Oncol; 2019 Aug; 14(4):369-374. PubMed ID: 31301016
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
